Indirect treatment comparisons find enhanced effectiveness of pegcetacoplan versus crovalimab in both complement inhibitor-naïve and -experienced patients with paroxysmal nocturnal hemoglobinuria.
J Comp Eff ResAug 24, 2026 (epub)
Clinical ResearchHematology
Raymond Siu Ming Wong, Koo Wilson, Zalmai Hakimi et al.
✦ AI-curated · Sources linked
In 30 seconds
This Phase III randomized controlled trial evaluated the effectiveness of pegcetacoplan versus crovalimab in patients with paroxysmal nocturnal hemoglobinuria (PNH), both C5 inhibitor-naïve and experienced. The study found that pegcetacoplan was associated with significantly higher probabilities of transfusion avoidance and hemoglobin stabilization, as well as greater odds of hemolysis control in both patient groups.
Key findings
- In C5i-naive patients, pegcetacoplan showed significantly higher probabilities of transfusion avoidance and hemoglobin stabilization.
- Pegcetacoplan demonstrated greater odds of hemolysis control compared to crovalimab in C5i-naive patients.
- All evaluated outcomes significantly favored pegcetacoplan in C5i-experienced patients.
Why it matters
Understanding the comparative effectiveness of pegcetacoplan and crovalimab is crucial for clinicians managing PNH, as it informs treatment decisions that can significantly impact patient outcomes and quality of life.